Open AccessPerforating dermatosis in a patient receiving azathioprine
Author(s) -
Emiliano Grillo,
Sergio VañóGalván,
Carmen Moreno,
Pedro Jaén
Publication year - 2013
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.108077
Subject(s) - azathioprine , medicine , purine metabolism , adverse effect , nucleotide , purine , purine analogue , mercaptopurine , dermatology , dna , immunology , pharmacology , pathology , biochemistry , biology , enzyme , gene , disease
Azathioprine (AZA) is an imidazole derivative of mercaptopurine. It antagonizes purine metabolism, and it may inhibit synthesis of DNA, RNA, and proteins. The 6-thioguanine nucleotides appear to mediate the majority of AZAs immunosuppressive and toxic effects. While cutaneous adverse side-effects are not uncommon, perforating dermatosis has not been reported in association to AZA. We speculate that immunological disorders induced by AZA in susceptible individuals could be related to perforating dermatosis